Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAPT AF-DES: Anti-Platelet and Thrombotic Strategy After 12 Months in AF Patients With DES
NCT04250116Phase 4Completed
- Sponsor
- Yonsei University
- Start
- Apr 2020
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of apixaban, rivaroxaban, clopidogrel in Atrial fibrillation (AFib), sponsored by Yonsei University. Started Apr 2020; status: completed.
02
Drugs
apixabanrivaroxabanclopidogrel
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT04250116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04250116.